News

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, ...
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
The pharmaceutical firm Novo Nordisk is pursuing a multipronged strategy to regain market share that it has lost to Eli Lilly ...
Novo Nordisk (NVO, NOVO-B.CO) said first-quarter sales of its first-to-market weight-loss drug Wegovy were 17.36bn Danish ...
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...
Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...